Active substance | asciminib |
Holder | Novartis |
Status | Running |
Indication | Patients with chronic myeloid leukemia (CML) in chronic phase previously treated with ≥ 2 TKIs |
Public documents | Approbation |
Approbation amendment | |
Information for the patient | |
Informed consent | |
Last update |
18/01/2024 |